Search results
Results from the WOW.Com Content Network
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York.The company was founded in 1988. [2] Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company branched out into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a ...
On 2 October 2020, Regeneron Pharmaceuticals announced that then-US President Donald Trump had received "a single 8 gram dose of REGN-COV2" after testing positive for SARS-CoV-2. [26] [27] The drug was provided by the company in response to a "compassionate use" (temporary authorization for use) request from the president's physicians. [26]
In 2014, Yancopoulos led the launch of the Regeneron Genetics Center, a major initiative in human genetic research that has sequenced exomes from over 1,000,000 people as of February 2020. [23] [24] Forbes magazine states Yancopoulos' financial stake in Regeneron has made him a billionaire. He is the first research and development chief in the ...
Regeneron commenced clinical testing of aflibercept in cancer in 2001. [25] In 2003, Regeneron signed a major deal with Aventis to develop aflibercept in the field of cancer. [ 26 ] In 2004 Regeneron started testing the compound, locally delivered, in proliferative eye diseases, [ 25 ] and in 2006 Regeneron and Bayer signed an agreement to ...
This page was last edited on 14 February 2021, at 14:06 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply.
[1] [2] It was developed by Regeneron Pharmaceuticals. [1] The most common side effects include cytokine release syndrome, infections, neutropenia, pyrexia (fever), anemia, thrombocytopenia, and diarrhea. [1] Odronextamab was approved for medical use in the European Union in August 2024. [1] [2]
Sanofi, in order to get out of its commitment, paid Regeneron $50 million and ceded the rights back to Regeneron. [2] The drug was a blockbuster generating $838 million in its first full year and sales increased 55% to $1.3 billion in 2013 [3] making Schleifer a billionaire. [2] In 2014 Eylea grossed $1.735 billion. [4]
The following table lists the largest biotechnology and pharmaceutical companies ranked by revenue in billion USD. The change column indicates the company's relative position in this list compared to its relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.